Clinical blockade of PD1 and LAG3—potential mechanisms of action

LT Nguyen, PS Ohashi - Nature Reviews Immunology, 2015 - nature.com
LT Nguyen, PS Ohashi
Nature Reviews Immunology, 2015nature.com
Dysfunctional T cells can render the immune system unable to eliminate infections and
cancer. Therapeutic targeting of the surface receptors that inhibit T cell function has begun to
show remarkable success in clinical trials. In this Review, we discuss the potential
mechanisms of action of the clinical agents that target two of these receptors, programmed
cell death protein 1 (PD1) and lymphocyte activation gene 3 protein (LAG3). We also
suggest correlative studies that may define the predominant mechanisms of action and …
Abstract
Dysfunctional T cells can render the immune system unable to eliminate infections and cancer. Therapeutic targeting of the surface receptors that inhibit T cell function has begun to show remarkable success in clinical trials. In this Review, we discuss the potential mechanisms of action of the clinical agents that target two of these receptors, programmed cell death protein 1 (PD1) and lymphocyte activation gene 3 protein (LAG3). We also suggest correlative studies that may define the predominant mechanisms of action and identify predictive biomarkers.
nature.com